Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Tebentafusp in Metastatic Uveal Melanoma
NCT07057596Phase 2Recruiting
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, TCR-Engineered T Cells, Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of tebentafusp in Uveal melanoma (UM). Started Jul 2025; status: recruiting.
02
Drugs
tebentafusp
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT07057596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07057596.